» Articles » PMID: 18804360

Impact of Pulmonary Hypertension on Gas Exchange and Exercise Capacity in Patients with Pulmonary Fibrosis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2008 Sep 23
PMID 18804360
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary hypertension is a relevant interceding morbidity in patients with pulmonary fibrosis that has significant impact on exercise tolerance and outcome. The aim of this study was to further characterize the exercise intolerance, dyspnoea and ventilatory inefficiency of patients with pulmonary fibrosis in the presence or absence of pulmonary hypertension via cardiopulmonary exercise testing. Thirty-four patients underwent pulmonary function testing, symptom-limited exercise testing on a bicycle and dyspnoea evaluation according to the BORG scale. Pulmonary hypertension was assessed by echocardiography and in a subset of patient's right heart catheterization. Sixteen of 34 patients with pulmonary fibrosis revealed pulmonary hypertension. While all study patients did not differ in lung functions and demographic characteristics, patients suffering from pulmonary hypertension showed a significantly impaired exercise tolerance and worsened ventilatory inefficiency. The extent of pulmonary artery pressure elevation impacted significantly on ventilatory inefficiency. In addition, the increased ventilatory requirements significantly influenced the extent of dyspnoea in patients with pulmonary hypertension. We conclude that pulmonary hypertension has a significant impact on exercise capacity and dyspnoea in patients with interstitial lung disease (ILD). The further impairment of exercise capacity as well as the extent of dyspnoea in patients with interceding PHT is attributable to a significantly impaired ventilatory inefficiency.

Citing Articles

Effects of High-Flow Nasal Cannula on Right Heart Dysfunction in Patients with Acute-on-Chronic Respiratory Failure and Pulmonary Hypertension.

Pelaia C, Armentaro G, Lupia C, Maiorano A, Montenegro N, Miceli S J Clin Med. 2023; 12(17).

PMID: 37685538 PMC: 10488050. DOI: 10.3390/jcm12175472.


The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry.

Stefanikova M, Doubkova M, Ovesna P, Sterclova M, Lacina L, Zurkova M BMC Pulm Med. 2023; 23(1):154.

PMID: 37138274 PMC: 10155319. DOI: 10.1186/s12890-023-02450-3.


Distinguishing exercise intolerance in early-stage pulmonary hypertension with invasive exercise hemodynamics: Rest V /VCO and ETCO identify pulmonary vascular disease.

Raza F, Dharmavaram N, Hess T, Dhingra R, Runo J, Chybowski A Clin Cardiol. 2022; 45(7):742-751.

PMID: 35419844 PMC: 9286332. DOI: 10.1002/clc.23831.


Comparison of heart rates at fixed percentages and the ventilatory thresholds in patients with interstitial lung disease.

Vonbank K, Lehmann A, Bernitzky D, Gysan M, Simon S, Krotka P Scand J Med Sci Sports. 2021; 32(4):754-764.

PMID: 34923682 PMC: 9304263. DOI: 10.1111/sms.14117.


Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency.

Gille T, Laveneziana P Eur Respir Rev. 2021; 30(162).

PMID: 34853093 PMC: 9489146. DOI: 10.1183/16000617.0355-2020.